Investor Summary
Fund Strategy
FUND PERFORMANCE AS OF 31st December 2025
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 8.1% | 0.2% | 2.8% |
| 2025 | 2024 |
|---|---|
| 2.8% | 14.2% |
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 8.1% | 0.2% | 2.8% |
| 2025 | 2024 |
|---|---|
| 2.8% | 14.2% |
Tourlite Fund returned 0.2% in Q4 2025 and 2.8% for the full year, underperforming targets due to disappointing long book stock selection in event-driven ideas. The short book generated meaningful alpha contributing 0.9% against strong market performance. Key holdings include FTAI Aviation, which announced FTAI Power initiative for data center power generation representing potential $1 billion EBITDA opportunity, and new position Montana Aerospace positioned to benefit from aerospace supply chain bottlenecks. The manager expects a bifurcated 2026 with favorable first half driven by economic growth, declining inflation, and Fed rate cuts, followed by increased caution as inflation reasserts. Portfolio maintains 20% net beta-adjusted exposure with concentration in industrials (50%), technology (25%), and consumer (20%). The strategy focuses on event-driven catalysts while maintaining selective short exposure in speculative themes, positioning for eventual momentum unwind when fundamentals reassert.
Event-driven long/short equity strategy focused on off-the-beaten-path investments with specific catalysts, particularly in aerospace and infrastructure sectors, while maintaining selective short exposure in overvalued speculative themes.
The manager expects a bifurcated 2026 with favorable first half driven by strong economic growth, declining inflation, and Fed rate cuts, followed by increased caution as inflation pressures reassert. This creates opportunity for risk-taking early in the year while positioning for potential generational short selling opportunities when momentum eventually breaks.
| Date | Letter | Tickers | Keywords | Pitches | Quick Takes |
|---|---|---|---|---|---|
| Jan 28 2026 | 2025 Q4 | AERO.SW, FIP, FTAI, GLNG, NFE, NTGR | aerospace, consumer, Event Driven, industrials, infrastructure, Long/Short, small cap, technology | - | Event-driven long/short fund underperformed in 2025 despite strong short book alpha generation. Key aerospace and infrastructure holdings FTAI Aviation and Montana Aerospace offer significant upside from supply chain dynamics and data center power opportunities. Manager expects bifurcated 2026 with early-year risk-taking opportunity followed by caution as inflation reasserts, maintaining selective positioning for momentum unwind. |
| Oct 21 2025 | 2025 Q3 | ABUS, APG, FIP, FTAI, IONQ, NFE, OMAB, QBTS, QUBT, RGTI, ROIV, SBSW, TIC | Aviation, fundamentals, infrastructure, Long/Short, Quality, SPACs, Speculation, value | - | Tourlite returned -2.0% in Q3 amid speculative market favoring momentum over fundamentals. Fund maintains long/short strategy with key positions in FTAI Aviation and Infrastructure, plus new SPAC investment TIC Solutions. Manager sees bubble forming in quantum computing and drone sectors, expecting eventual reversal to create generational short opportunities for disciplined fundamental investors. |
| May 23 2025 | 2025 Q1 | ABUS, COST, FIP, FTAI, GRAL, IMVT, NFE, OABI, ROIV, SOC, WMT | Biotech, consumer, energy, Event Driven, industrials, infrastructure, Long/Short, tariffs |
SOC FIP FTAI |
Tourlite returned -4.6% in Q1 2025 while maintaining cautious positioning around 30% net exposure. The fund focuses on event-driven longs like Sable Offshore and FTAI Infrastructure while shorting overvalued consumer companies. Trump's tariff policies create macro headwinds, but the manager sees compelling opportunities in biotech special situations and shorting frothy sectors like AI and crypto. |
| Feb 18 2025 | 2024 Q4 | FIP, FTAI, IMVT, LTCH, REAL, ROIV, SOC | aerospace, Biotechnology, consumer, energy, industrials, Long/Short, small cap, technology |
FTAI REAL FIP LTCH SOC ROIV |
Tourlite delivered 14.2% returns in 2024 while maintaining near-zero net exposure in an overvalued market. FTAI Aviation drove performance with 200%+ gains from aerospace aftermarket strength and new aircraft acquisition initiative. Manager sees current speculative rally as reminiscent of late 2021, creating attractive short opportunities while positioning for multiple 2025 catalysts across aerospace, energy, and biotech holdings. |
| Oct 21 2024 | 2024 Q3 | ABUS, APG, FTAI, ROIV, SBUX, SOC, ULTA, WMT | aerospace, consumer, Correlation, healthcare, industrials, Long/Short, technology, volatility |
SOC FTAI ROIV ABUS APG |
Tourlite delivered 4.5% in Q3 through market-neutral long/short strategy, maintaining near-zero net exposure while capturing alpha from individual stock selection. Key winners included Sable Offshore pipeline catalyst and FTAI Aviation's raised guidance. Manager remains cautious on broad markets but optimistic about stock-picking opportunities as correlations decrease and fundamentals become more important than market tailwinds. |
| Aug 1 2024 | 2024 Q2 | FIP, FTAI, IMVT, LTCH, OABI, PRPL, REAL, RICK | aerospace, Biotechnology, consumer, industrials, infrastructure, Long/Short, small caps, special situations |
FTAI FIP LTCH OABI RICK PRPL |
Tourlite delivered 2.7% in Q2 through a concentrated long/short strategy targeting out-of-favor small caps with multi-year value creation potential. FTAI Aviation and Infrastructure drove performance while biotech special situations OmniAb and Roivant offer asymmetric upside. Despite maintaining cautious market outlook amid inflation and election risks, the manager sees favorable conditions for selective stock-picking. |
| May 9 2024 | 2024 Q1 | ABUS, APG, ESPR, FIP, FTAI, LGND, OABI, PRGO, PRPL, ROIV | Biotechnology, Hedging, Idiosyncratic, Long/Short, spinoffs, value |
FIP FTAI APG PRPL ESPR ROIV PRGO |
Tourlite Fund delivered 6.0% returns in Q1 through focused long/short strategy targeting idiosyncratic opportunities. Manager maintains conservative market outlook while positioning in spinoffs, litigation plays, and undervalued companies with specific catalysts. Low net exposure strategy with concentrated biotech allocation and emphasis on company-specific events expected to drive returns independent of broader market performance. |
| Jan 26 2024 | 2023 Q4 | APG, ESPR, FC, FIP, FTAI, IMVT, KD, LTCH, PRM, PRVB, ROIV, SAN.PA | Aviation, Biotechnology, Event Driven, Long/Short, small caps, special situations |
FTAI APG ESPR FIP BKD LTCH ROIV AFCG |
Long/short small-cap fund returned 8.8% in 2023, outperforming Russell 2000 through catalyst-driven biotechnology and aviation investments. Key positions include Roivant Sciences biotech consolidation play and FTAI Aviation structural turnaround. Manager maintains low net exposure amid rising rates but sees favorable 2024 setup with compelling long opportunities and new short ideas from market rally. |
| Oct 31 2023 | 2023 Q3 | FIP, FTAI, KD, LTCH | arbitrage, consumer, Event Driven, industrials, Long/Short, small cap, special situations |
FTAI BKD LTCH FIP |
Long/short equity fund with 7.8% Q3 return driven by event-driven arbitrage and catalyst-driven shorts. Low net exposure strategy focuses on special situations with concrete catalysts. Portfolio concentrated in industrials and consumer sectors. Manager maintains conservative market outlook amid rising rates while appropriately sizing high-conviction opportunities with near-term catalysts. |
| Jan 9 2023 | 2023 Q2 | APG, FIP, FTAI, GLOP, KD, LESL, LTCH, PRM | AI, Aviation, consumer, industrials, Long/Short, Recession, small caps, technology |
LTCH APG FIP FTAI KPRMILL IN BKD |
Long/short equity fund with defensive positioning exploiting valuation disparities in small/mid-cap names. Strong long book performance offset by AI-driven short squeeze. Manager maintains cautious economic outlook despite market optimism, positioning for potential reversal in rally and correction of fundamental disconnects. Focus on earlier loss recognition while preserving core fundamental analysis approach. |
| Apr 18 2023 | 2023 Q1 | FC, FTAI, GLOP, VRRM | - | - | |
| Feb 17 2023 | 2022 Q4 | APG, PACK, PRM, PRVBX, VRRM | - | - | |
| Oct 24 2022 | 2022 Q3 | PRM, VRRM | - | - | |
| Jul 14 2022 | 2022 Q2 | AMZN, GOOG, IS, PRM, U | - | - |
| QUARTER | THEMES | TAGS |
|---|---|---|
| 2025 Q4 |
AIAI infrastructure plays dominated 2025 returns with 65% of Russell 2000's return coming from AI infrastructure. The manager views this as a concentrated market levered to a singular theme - essentially a bet on how much CAPEX five companies will spend building data centers. The concentration around AI infrastructure spending creates both opportunities and risks in a historically concentrated market. |
Infrastructure Data Centers CAPEX Concentration |
Small CapsSmall caps continued to underperform large caps in 2025, with returns dominated by AI infrastructure plays and speculative unprofitable companies. The manager notes extreme bifurcation in performance between unprofitable stocks and quality stocks, creating valuation disparities at historic extremes. Quality businesses now trade at historically cheap multiples. |
Russell 2000 Quality Valuation Underperformance | |
QualityThe manager highlights extreme bifurcation between unprofitable stocks and quality stocks, with quality businesses trading at historically cheap multiples. This creates significant valuation disparities between winners and losers that have reached historic extremes, presenting opportunities for quality-focused investors. |
Valuation Multiples Bifurcation Cheap | |
| 2025 Q3 |
Long/ShortFund operates as a long/short equity strategy capturing spread between long and short positions. Focuses on higher-quality businesses with positive earnings momentum on the long side while shorting companies with deteriorating fundamentals or unsustainable business models. |
Long/Short Alpha Spread Fundamentals Quality |
InfrastructureSignificant exposure to infrastructure assets through FTAI Infrastructure including rail assets, energy storage facilities like Repauno, and power generation facilities like Long Ridge. Views these as long-term value creation opportunities with multiple expansion catalysts. |
Rail Energy Storage Power Generation Infrastructure Assets | |
AviationMajor position in FTAI Aviation with strong fundamentals and growing market adoption. Multiple catalysts expected including investor day, FAA approval for third PMA part, and potential second Strategic Capital Initiative vehicle launch. |
Aviation PMA FAA Strategic Capital Growth | |
SPACsInvestment in TIC Solutions which was taken public via SPAC by Martin Franklin. Draws parallels to successful APi Group SPAC investment that increased fivefold over six years, seeing similar value creation trajectory potential. |
SPAC Martin Franklin Value Creation APi Group Transformation | |
| 2025 Q1 |
BiotechnologyThe fund continues to see meaningful mispricing across select biotech companies, highlighting positions in Roivant, Arbutus, Immunovant, OmniAb, and Grail. Despite short-term volatility from macro headlines and policy developments, these companies trade at substantial discounts to intrinsic value, offering significant upside with a margin of safety over the long term. |
Biotech Mispricing Spinoff Intrinsic Value Margin of Safety |
EnergySable Offshore has made substantial progress restarting operations at the Santa Ynez Unit offshore asset acquired from Exxon. The California Coastal Commission has retreated from previous attempts to exert authority, and Sable is pursuing $268 million in damages. Production has resumed from six wells with oil sales expected to begin in July. |
Offshore Production Pipeline E&P California | |
InfrastructureFTAI Infrastructure is approaching a fundamental inflection point after years of groundwork, poised to more than double earnings with run-rate EBITDA expected to hit $300 million by year-end. Multiple growth levers include datacenter development, incremental contracts, M&A pipeline, and further progress at Repauno with phase 3 permitting. |
EBITDA Datacenter Contracts M&A Inflection | |
AviationFTAI Aviation has multiple positive catalysts including PMA approval and continued progress on its Strategic Capital Initiative. Through its first SCI fund, FTAI raised $4 billion in debt and equity to acquire mid-life aircraft, targeting a $30 billion market opportunity and securing associated engine maintenance contracts. |
Aircraft Leasing Maintenance PMA Strategic Capital | |
Trade PolicyTrump's renewed tariff threats and diminished concern for near-term stock market performance began weighing on indexes. Investors struggled to interpret intentions as tariffs signaled geopolitical strength but risked fueling inflation, running counter to stated goals of cutting interest rates and reducing the deficit. |
Tariffs Trump Inflation Geopolitical Policy | |
| 2024 Q4 |
AerospaceFTAI Aviation emerged as a top performer with over 200% share price increase driven by aerospace aftermarket tailwinds and growing PMA parts business market share. The company announced FAA approval for its second PMA engine part and launched a Strategic Capital Initiative to acquire mid-life aircraft, tapping into a $30 billion market opportunity. Management projects this initiative will generate approximately $200 million in incremental annual aerospace EBITDA by 2026. |
Aftermarket PMA Parts Aircraft Leasing Maintenance FAA Approval |
EnergySable Offshore acquired an offshore asset from Exxon off the California coast that had been shut down following a pipeline spill. Despite regulatory delays from the California Coastal Commission, the manager believes Sable has legal rights to resume production and that these obstacles are temporary. The manager views Sable as significantly undervalued relative to the quality of its oil assets, which rank among the best in the US. |
Offshore Oil Assets Regulatory Production Valuation | |
BiotechnologyRoivant offers attractive risk-reward with multiple ways to win, including exposure to LNP litigation through its Arbutus stake that could be worth up to $4 per share. Excluding cash and Immunovant stake, the remainder of Roivant is valued at less than $2 per share. The manager maintains positions in both Roivant and Arbutus as part of this biotech investment thesis. |
LNP Litigation Arbutus Immunovant Valuation Risk-Reward | |
| 2024 Q3 |
AerospaceFTAI Aviation benefits from strong aerospace aftermarket tailwinds, with Boeing issues providing additional upside. The company exceeded Q2 expectations and raised 2026 EBITDA guidance by 25% to $1.25 billion. Significant valuation gap exists between FTAI and aerospace aftermarket peers. |
Aftermarket Boeing EBITDA Valuation Growth |
BiotechnologyRoivant launched new pipeline program Mosliciguat with significant future opportunities. The acquisition demonstrates Roivant's platform value and disciplined capital allocation. Positive updates from Immunovant and progress on 1402 further benefited share price. |
Pipeline Platform Immunovant Capital Allocation Development | |
OilSable Offshore acquired offshore asset from Exxon off California coast that was shut down following pipeline spill. Company received approval to restart pipeline and research indicated settlement was likely for required permits. Position initiated ahead of key catalyst. |
Offshore Pipeline Permits Catalyst Settlement | |
| 2024 Q2 |
AerospaceFTAI Aviation benefits from aerospace market tailwinds with ongoing OEM shortfalls resulting in higher lease rates and extensions. The company announced V2500 as its second focus engine with EBITDA expected to grow from $40 million to $100 million by 2026. Multiple catalysts remain for the remainder of the year including potential PMA parts approvals. |
Aircraft Leasing Aviation Services Aerospace Components Aftermarket Engine |
BiotechnologyPortfolio includes biotech special situations including Roivant and OmniAb, viewed as longer duration assets on a path to creating significant shareholder value. OmniAb presents compelling asymmetric opportunities as a holder of royalties on future drug sales, with royalty on Immunovant alone potentially accounting for 50-100% of current market cap. |
Drug Royalties Biotech Pharmaceuticals Special Situations Asymmetric | |
InfrastructureFTAI Infrastructure is viewed as being at an inflection point similar to where FTAI was a year ago. As several assets continue to mature, acceleration in earnings and potential monetization of certain assets is expected. Long Ridge Energy Terminal asset has significant upside potential for conversion to host data centers. |
Infrastructure Data Centers Energy Terminal Asset Monetization Earnings | |
| 2024 Q1 |
BiotechnologyFund maintains four biotech long positions representing ~20% of gross long exposure, viewed as idiosyncratic opportunities based on litigation or corporate events rather than binary drug results. Positions include Roivant Sciences with significant cash position and share buyback program, Arbutus benefiting from Covid vaccine litigation, OmniAb spinoff with 300+ drugs in pipeline, and a recent spinoff trading at 65% discount to cash. |
Litigation Spinoffs Royalties Pipeline Cash |
SpinoffsManager focuses on spinoff opportunities including OmniAb spun from Ligand Pharmaceuticals and a recent biotech spinoff trading at 65% discount to cash due to forced selling. These situations provide asymmetric risk-reward profiles with temporary dislocations creating attractive entry points. |
Forced Selling Valuation Discount Asymmetric Dislocation | |
| 2023 Q4 |
BiotechnologyFund initiated significant position in Roivant Sciences, a biotech company specializing in consolidating promising drug patents. Thesis based on cash value from asset sales, Immunovant stake, and pipeline upside potential. Also held Provention Bio which was acquired by Sanofi following FDA approval. |
Drug Development M&A Patents FDA Approval Pipeline |
AviationFTAI Aviation was significant positive contributor based on undervaluation from partnership structure and infrastructure spin-off. Aviation segment saw meaningful inflection in business fundamentals with modular factory proving time-efficient and low-cost solution. |
Aircraft Parts Manufacturing Spin-offs Cash Flow | |
Special SituationsFund engaged in event-driven arbitrage opportunities and catalyst-driven investments. Recognized broad nature of special situations category and consolidated these within respective longs and shorts for clearer presentation. |
Event Driven Arbitrage Catalysts Risk Reward | |
| 2023 Q3 |
Event DrivenThe fund initiated positions in two event-driven arbitrage opportunities during the quarter, both contributing to performance. These involved identifying concrete catalysts that would lead to price convergence of securities with the same economic values. One position was previously unprofitable but gained conviction following positive change in management alignment. |
Arbitrage Catalysts Special Situations Merger Convergence |
Short SellingThe fund maintains an active short portfolio with catalyst-driven shorts targeting overvalued companies with imminent catalysts. They scaled back aggressive short exposure to higher beta stocks during the quarter as prices declined. Two companies are shorted due to recent lockup expirations and one needing near-term capital. |
Overvalued Lockups Beta Catalyst Downside | |
| 2023 Q2 |
AIManager notes AI hype has driven market strength in large cap tech but has negatively impacted their short positions. They observe significant disparity between AI company valuations and underlying business fundamentals, with one undisclosed short benefiting from AI hype despite anticipated weaker demand and misleading profitability metrics. |
Artificial Intelligence Technology Valuations Hype |
EarningsManager maintains cautious stance on companies' earnings despite market optimism. They believe a recession could result in significant decrease in earnings and lead to multiple contractions, noting earnings expectations have seen only modest decline compared to past instances. |
Corporate Earnings Recession Multiples | |
Small CapsFund's long portfolio consists mostly of small and mid-cap technology companies that have not benefited from flows into large cap indexes. Manager notes these companies have underperformed relative to large cap tech during the AI-driven rally. |
Small Cap Mid Cap Technology Underperformance | |
AviationManager is bullish on FTAI Aviation due to rising CFM56 engine lease rates driven by increased interest rates, delivery shortages, and reliability issues with next-gen aircraft. They expect significant growth in shop visits and believe FTAI is well-positioned with its modular factory and PMA parts approval. |
Aircraft Engine Leasing Maintenance |
| Date | Pitch Type | Author | Ticker | Company | Industry | Sub Industry | Bull / Bear | Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| May 23, 2025 | Fund Letters | Tourlite Capital Management | SOC | Sable Offshore | Energy | Oil & Gas Exploration & Production | Bull | NASDAQ | Asset Restart, California, E&P, Offshore, Oil & Gas, Operational Turnaround, pipeline, Production Ramp, Regulatory Resolution | Login |
| May 23, 2025 | Fund Letters | Tourlite Capital Management | FTAI | FTAI Aviation | Industrials | Aerospace & Defense | Bull | NASDAQ | Aftermarket Maintenance, Aircraft Leasing, Aviation, EBITDA growth, Engine Maintenance, PMA Approval, Short squeeze, Strategic Capital Initiative | Login |
| May 23, 2025 | Fund Letters | Tourlite Capital Management | FIP | FTAI Infrastructure | Industrials | Industrial Conglomerates | Bull | NASDAQ | Contract Growth, datacenter, EBITDA inflection, infrastructure, M&A Pipeline, Power generation, Refinancing, Value Inflection | Login |
| Feb 18, 2025 | Fund Letters | Tourlite Capital Management | FTAI | FTAI Aviation | Industrials | Aerospace & Defense | Bull | NASDAQ | Aerospace, aftermarket, Aircraft Leasing, EBITDA growth, Maintenance, PMA Parts, Strategic Capital Initiative, Value-Add Business Model | Login |
| Feb 18, 2025 | Fund Letters | Tourlite Capital Management | REAL | RealReal | Consumer Discretionary | Internet & Direct Marketing Retail | Bull | NASDAQ | Broken Stocks, CEO transition, Contrarian Investment, debt refinancing, Guidance Raise, Luxury Consignment, market overreaction, turnaround | Login |
| Feb 18, 2025 | Fund Letters | Tourlite Capital Management | FIP | FTAI Infrastructure | Industrials | Industrial Conglomerates | Bull | NASDAQ | Accretive Acquisition, Asset Inflection, data center, debt refinancing, infrastructure, Long Ridge, Multiple Catalysts, Undervalued Position | Login |
| Feb 18, 2025 | Fund Letters | Tourlite Capital Management | LTCH | Latch | Technology | Technology Hardware, Storage & Peripherals | Bull | NASDAQ | CEO transition, deep value, Discount to cash, Execution Challenge, Financial Filings, Operational Performance, regulatory compliance, Uplisting Catalyst | Login |
| Feb 18, 2025 | Fund Letters | Tourlite Capital Management | ROIV | Roivant | Health Care | Biotechnology | Bull | NASDAQ | Arbutus, biotechnology, Immunovant, LNP Litigation, Multiple Ways to Win, risk/reward, Stub Value, Sum-of-parts | Login |
| Feb 18, 2025 | Fund Letters | Tourlite Capital Management | SOC | Sable Offshore | Energy | Oil, Gas & Consumable Fuels | Bull | NYSE | California, call options, offshore oil, pipeline, Production Restart, Regulatory Approval, Santa Ynez Unit, Trump administration, Undervalued Assets | Login |
| Oct 21, 2024 | Fund Letters | Tourlite Capital Management | SOC | Sable Offshore | Energy | Oil & Gas Exploration & Production | Bull | NASDAQ | California, Catalyst, E&P, Event-driven, Offshore, pipeline, Regulatory Approval | Login |
| Oct 21, 2024 | Fund Letters | Tourlite Capital Management | FTAI | FTAI Aviation | Industrials | Aerospace & Defense | Bull | NASDAQ | Aerospace, aftermarket, Aviation, Boeing, EBITDA growth, growth, valuation gap | Login |
| Oct 21, 2024 | Fund Letters | Tourlite Capital Management | ROIV | Roivant Sciences | Health Care | Biotechnology | Bull | NASDAQ | biotechnology, capital allocation, drug development, Immunovant, Mosliciguat, pipeline, platform | Login |
| Oct 21, 2024 | Fund Letters | Tourlite Capital Management | ABUS | Arbutus Biopharma | Health Care | Biotechnology | Bull | NASDAQ | biotechnology, Hepatitis B, Intellectual Property, LNP Litigation, Roivant, Special Situation | Login |
| Oct 21, 2024 | Fund Letters | Tourlite Capital Management | APG | APi Group | Industrials | Commercial Services & Supplies | Bull | NYSE | capital allocation, contrarian, industrial services, margin expansion, Value | Login |
| Aug 1, 2024 | Fund Letters | Tourlite Capital Management | OABI | OmniAb | Health Care | Biotechnology | Bull | NASDAQ | Antibody Discovery, asymmetric opportunity, biotechnology, cash flow, drug development, insider buying, royalties | Login |
| Aug 1, 2024 | Fund Letters | Tourlite Capital Management | PRPL | Purple Innovation | Consumer Discretionary | Household Durables | Bull | NASDAQ | Broken Stocks, Free Cash Flow, home improvement, housing cycle, Mattresses, new management, turnaround | Login |
| Aug 1, 2024 | Fund Letters | Tourlite Capital Management | FIP | FTAI Infrastructure | Industrials | Transportation Infrastructure | Bull | NASDAQ | Asset Maturation, data centers, earnings acceleration, Energy Terminal, Inflection Point, infrastructure, monetization | Login |
| Aug 1, 2024 | Fund Letters | Tourlite Capital Management | FTAI | FTAI Aviation | Industrials | Aerospace & Defense | Bull | NASDAQ | Aerospace, Aviation Leasing, EBITDA growth, Engine Aftermarket, OEM Shortfalls, PMA Parts, valuation gap | Login |
| Aug 1, 2024 | Fund Letters | Tourlite Capital Management | LTCH | Latch | Information Technology | Technology Hardware & Equipment | Bull | NASDAQ | Cash Value, Discount Valuation, rebranding, Smart Access, Strategic Transformation, technology hardware | Login |
| Aug 1, 2024 | Fund Letters | Tourlite Capital Management | RICK | RCI Hospitality Holdings | Consumer Discretionary | Hotels, Restaurants & Leisure | Bull | NASDAQ | cash flow, hospitality, insider ownership, low valuation, same-store sales, share repurchases, Value | Login |
| Apr 24, 2024 | Fund Letters | Tourlite Capital Management | FIP | FTAI Infrastructure | Industrials | Transportation Infrastructure | Bull | NASDAQ | Asset Optimization, balance sheet, Car Repair, infrastructure, railroad, Terminal, Throughput, Transportation | Login |
| Apr 24, 2024 | Fund Letters | Tourlite Capital Management | APG | APi Group | Industrials | Commercial Services & Supplies | Bull | NYSE | Chubb Integration, cross-selling, Elevator Maintenance, industrial services, recurring revenue, share repurchase, Tuck-in M&A, Value | Login |
| Apr 24, 2024 | Fund Letters | Tourlite Capital Management | ROIV | Roivant Sciences | Health Care | Biotechnology | Bull | NASDAQ | biotechnology, Brepocitinib, cash position, Patent Litigation, Phase 3, royalties, share repurchase, Uveitis | Login |
| Apr 24, 2024 | Fund Letters | Tourlite Capital Management | ESPR | Esperion Therapeutics | Health Care | Biotechnology | Neutral | NASDAQ | biotechnology, Cash runway, Catalyst, Event-driven, litigation, settlement, Special situations | Login |
| Apr 24, 2024 | Fund Letters | Tourlite Capital Management | PRPL | Purple Innovation | Consumer Discretionary | Household Durables | Bull | NASDAQ | Asymmetric, Broken Stocks, business model, Consumer Discretionary, Housing, Mattresses, new management, turnaround | Login |
| Apr 24, 2024 | Fund Letters | Tourlite Capital Management | PRGO | Perrigo | Health Care | Pharmaceuticals | Bull | NYSE | Birth Control, Consumer healthcare, Facility Reset, Infant Formula, Normalized Earnings, Opill, OTC, transformation | Login |
| Apr 24, 2024 | Fund Letters | Tourlite Capital Management | FTAI | FTAI Aviation | Industrials | Aerospace & Defense | Bull | NASDAQ | Aerospace, Aircraft Leasing, Aircraft Shortage, Aviation, Maintenance, Modular Factory, PMA Approval | Login |
| Sep 1, 2023 | Fund Letters | Tourlite Capital Management | FTAI | FTAI Aviation | Industrials | Aerospace & Defense | Bull | NASDAQ | Aviation, CFM56, Engine Leasing, growth, maintenance services, Modular Factory, PMA Parts | Login |
| Sep 1, 2023 | Fund Letters | Tourlite Capital Management | KPRMILL IN | Perimeter Solutions | Materials | Chemicals | Neutral | NYSE | capital allocation, Chemicals, Competition, exit, Fire Retardants, market share, Timing Risk | Login |
| Sep 1, 2023 | Fund Letters | Tourlite Capital Management | BKD | Kyndryl | Information Technology | IT Services | Bull | NYSE | IBM, Infrastructure Services, IT services, Management Buyback, margin expansion, spinoff, turnaround | Login |
| Sep 1, 2023 | Fund Letters | Tourlite Capital Management | LTCH | Latch | Information Technology | Technology Hardware, Storage & Peripherals | Bull | NASDAQ | Delisted, new management, proptech, Smart Access, technology, turnaround, Value | Login |
| Sep 1, 2023 | Fund Letters | Tourlite Capital Management | APG | APi Group | Industrials | Commercial Services & Supplies | Bull | NYSE | Free Cash Flow, industrial services, margin expansion, recurring revenue, Safety Services, turnaround, Value | Login |
| Sep 1, 2023 | Fund Letters | Tourlite Capital Management | FIP | FTAI Infrastructure | Energy | Oil, Gas & Consumable Fuels | Bull | NASDAQ | capital structure, cash flow generation, Energy Terminals, infrastructure, long-term contracts, overlooked, Value | Login |
| Oct 31, 2023 | Fund Letters | Tourlite Capital Management | FTAI | FTAI Aviation | Industrials | Aerospace & Defense | Bull | NASDAQ | Aerospace, Aviation, Cost efficiency, Modular Factory, Parts Manufacturing, PMA Approval, Regulatory Approval | Login |
| Oct 31, 2023 | Fund Letters | Tourlite Capital Management | BKD | Kyndryl | Information Technology | IT Services | Bull | NYSE | Contract Transition, IT services, Legacy Backlog, margin expansion, Operational Turnaround, Profitability Improvement | Login |
| Oct 31, 2023 | Fund Letters | Tourlite Capital Management | LTCH | Latch | Information Technology | Technology Hardware & Equipment | Bull | NASDAQ | Delisting, Financial Restatement, Forced Selling, proptech, regulatory compliance, Smart Access, Special Situation | Login |
| Oct 31, 2023 | Fund Letters | Tourlite Capital Management | FIP | FTAI Infrastructure | Industrials | Transportation Infrastructure | Bull | NASDAQ | asymmetric upside, cash flow generation, Non-Recourse Debt, Port Terminal, railroad, Sum-of-parts, Transportation Infrastructure, Value | Login |
| Jan 26, 2024 | Fund Letters | Tourlite Capital Management | ROIV | Roivant Sciences | Health Care | Biotechnology | Bull | NASDAQ | Asymmetric, biotechnology, drug development, holding company, Patent Litigation, pipeline, Sum-of-parts, value creation | Login |
| Jan 26, 2024 | Fund Letters | Tourlite Capital Management | AFCG | Franklin Covey | Consumer Discretionary | Diversified Consumer Services | Bull | NYSE | Activist Catalyst, Asset Sale, Education Division, share repurchases, strategic review, Training Services, Value | Login |
| Jan 26, 2024 | Fund Letters | Tourlite Capital Management | FTAI | FTAI Aviation | Industrials | Aerospace & Defense | Bull | NASDAQ | Aerospace, Aviation, C-Corp, cash flow growth, Leasing, Modular Factory, PMA Parts, spin-off | Login |
| Jan 26, 2024 | Fund Letters | Tourlite Capital Management | APG | APi Group | Industrials | Commercial Services & Supplies | Bull | NYSE | Chubb Integration, FCF yield, industrial services, margin expansion, recurring revenue, Value | Login |
| Jan 26, 2024 | Fund Letters | Tourlite Capital Management | ESPR | Esperion Therapeutics | Health Care | Biotechnology | Neutral | NASDAQ | biotechnology, Cash runway, Catalyst, Event-driven, Litigation Settlement, Special Situation | Login |
| Jan 26, 2024 | Fund Letters | Tourlite Capital Management | FIP | FTAI Infrastructure | Real Estate | Specialized REITs | Bull | NASDAQ | Asset Sale, debt refinancing, infrastructure, Jefferson Terminal, Preferred Redemption, Transtar, value unlocking | Login |
| Jan 26, 2024 | Fund Letters | Tourlite Capital Management | BKD | Kyndryl | Information Technology | IT Services | Bull | NYSE | backlog conversion, Customer Stickiness, IT services, long-term contracts, margin expansion, spin-off, turnaround | Login |
| Jan 26, 2024 | Fund Letters | Tourlite Capital Management | LTCH | Latch | Information Technology | Technology Hardware, Storage & Peripherals | Bull | OTC | Accounting Issues, CEO change, deep value, Delisting, Ring Founder, Smart Home Technology, turnaround | Login |
| TICKER | COMMENTARY |
|---|---|
| AERO.SW | We recently initiated a position in Montana Aerospace, a Swiss-listed aerostructures manufacturer trading at a significant discount to intrinsic value. The aerospace supply chain is facing a severe bottleneck, while Boeing and Airbus build rates should inflect positively to meet decade-high demand, the legacy tiered supplier base remains fractured and financially distressed following years of disruption. We believe vertically integrated Montana, for which 90% of products are single-sourced, is positioned to be the structural winner. |
| FIP | Looking ahead to 2026, we expect FIP to take strategic action with Long Ridge, refinance its bridge loan from the Wheeling acquisition, and potentially divest Repauno as the company continues its transition toward a pure-play rail business. As these catalysts unfold, we believe FIP could be worth more than $15 per share over the next year. |
| FTAI | FTAI Aviation is a leading MRO franchise for the CFM56 and is in the midst of transforming into a capital-light, high-visibility model with its Strategic Capital Initiative (SCI), protected by an irreplaceable competitive advantage in PMA parts. And yet, the market has continued to value the company as a cyclical lessor despite clear operating leverage and a qualitative shift toward a more scalable, capital-efficient industrial model. |
| GLNG | We also sold Golar LNG (Bermuda), as earnings in 2026 will be impacted by the completion of its contract and the relocation of its Hilli FLNG vessel. |
| NFE | New Fortress Energy appeared as a detractor in both Q4 2025 and full year 2025 performance tables. |
| NTGR | Other detractors included Edgewell Personal Care, security systems company Arlo Technologies, communications equipment business Netgear. Netgear's decline was primarily due to concerns over supply chain issues, rising memory costs, and a mixed outlook from management during its third quarter earnings call. |
| Ticker | Put/Call | Amount Bought | Shares Bought | % Change | Weight % |
|---|---|---|---|---|---|
| No Recent Buys Data | |||||
| Ticker | Put/Call | Amount Sold | Shares Sold | % Change | Weight % | Status |
|---|---|---|---|---|---|---|
| No Recent Sells Data | ||||||
| Industry | Prev Quarter % | Current Quarter % | Change |
|---|---|---|---|
| No industry data available | |||